MHE Staff

Type 1 diabetes is an autoimmune disease that affects more than 2 million Americans.

An administration change in November could see the return of closed borders or increased protections for immigrants.

Undocumented individuals are ineligible for the Affordable Care Act (ACA) or federally funded Medicaid, but some states offer state-sponsored coverage for certain immigration statuses, such as Temporary Protected Status.

Immigrant children need a variety of resources when they come to the United States.

Company officials said a challenging reimbursement environment and escalating operating costs created a lack of profitability for the business.

In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about the disappointment surrounding the uptake of Humira biosimilars.

In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about whether or not she favors ending interchangeability designation for biosimilars.

Walgreens is expanding its specialty pharmacy services and renaming AllianceRx Walgreens Pharmacy as Walgreens Specialty Pharmacy.

Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.

This week, the annual meeting of the Academy of Managed Care Pharmacy (AMCP) will bring 3,400 pharmacy, payers and industry leaders to New Orleans.

Datopotamab deruxtecan, which is being reviewed to treat adults with HR-positive, HER2-negative breast cancer, has an FDA target date in the first quarter of 2025. Datopotamab deruxtecan also is under FDA review for non-small cell lung cancer.

We need your views! Help us help you.

A recent survey on primary care spending showed the U.S. lagging behind.

Tthe FDA approved Kevzara (sarilumab),an interleukin-6 receptor inhibitor, last year. It may help people with polymyalgia rheumatica ease off taking glucocorticoids.

The results of this week’s poll about the Affordable Care Act.

J&J’s Opsynvi is single-tablet combination of macitentan, an endothelin receptor antagonist, and tadalafil, a PDE5 inhibitor. It will be priced on parity with Opsumit, which is also a J&J product to treat patients with PAH.

The 14th anniversary of the Affordable Care Act was this past Saturday.

The results of this week’s poll about whether copay accumulators should be banned.

About 20 states have moved to ban copay accumulators.

PQA is the national quality organization dedicated to improving medication safety, adherence, appropriate use and medication management services.

Povorcitinib, an oral JAK1 inhibitor, shows promise in treating prurigo nodularis, a chronic, inflammatory skin disease.

The results of this week’s poll about Medicare cap extension.

Almost 20,000 dermatologists attended the annual meeting this weekend at the San Diego Convention Center.

The submission is for the same indications, including Xolair’s recently approved indication IgE-mediated food allergy.

The clinical associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, spoke in a session over the weekend at the American Academy Dermatology meeting about conditions that may mimic atopic dermatitis.

Should the Medicare $2,000 per year cap on out-of-pocket costs for prescription drugs be extended to commercial insurance?

In a discussion with Managed Healthcare Executive, Robert Sidbury, M.D., M.P.H, FAAD, professor of pediatrics at the Seattle Children's Hospital talks about what it takes to run a dermatology practice and how to implement value-based care initiatives.

At the American Academy of Dermatology meeting in San Diego, Raj J. Chovatiya, M.D., Ph.D, discussed the evolution of studies on Jak inhibitors post-approval.